Adam's Take - Page 2 of 5

Adam's Take

A tiny fish-oil drug rival trash talks Amarin, but there’s still much to prove

By Adam Feuerstein

Adam's Take

Omeros claims a failed drug study was ‘positive.’ Investors were not fooled

By Adam Feuerstein

Adam's Take

Ahead of Geron blowup, warning signs were visible for those willing to see them

By Adam Feuerstein

Adam's Take

TG Therapeutics’ credibility vanishes with blood cancer drug trial setback

By Adam Feuerstein

Adam's Take

Amarin has investors buzzing about fish oil. Here’s where this biotech feel-good story goes next

By Adam Feuerstein

Adam's Take

Galectin Therapeutics buries bad news in the hype of a combination cancer drug trial

By Adam Feuerstein

Adam's Take

Global Blood’s FDA filing plan for a sickle cell drug is riskier than you think

By Adam Feuerstein

Adam's Take

Amgen emerges as new multiple myeloma drug player, threatening Bluebird, Celgene

By Adam Feuerstein

Adam's Take

Answers to biotech’s burning questions for 2018: winners, floppers, and procrastinators

By Adam Feuerstein

Adam's Take

Can plastic tubes stop livers from failing? Unlikely, but a biotech keeps trying

By Adam Feuerstein

Adam's Take

A gene therapy for overactive bladder? A waste of time and money that trivializes a lifesaving technology

By Adam Feuerstein

Business

Investors are pouring more money into biotech funds, and stocks are responding

By Adam Feuerstein

Adam's Take

Geron’s prodigious fundraising activity signals low confidence in J&J relationship

By Adam Feuerstein

Adam's Take

Gilead Sciences’ board is looking for a new CEO. Here’s a list of possible contenders

By Adam Feuerstein

Adam's Take

Gilead’s golden era ends with the executive departures of ‘The Johns’

By Adam Feuerstein

Adam's Take

ResTORbio drug study results weaken under scrutiny

By Adam Feuerstein

Adam's Take

Preclinical biotech companies are having an IPO bonanza. What’s the draw for investors?

By Adam Feuerstein

Adam's Take

Celgene is perking up. Here’s what needs to happen for the momentum to continue

By Adam Feuerstein

Adam's Take

Red flags fly over Anavex: What’s stopping the drug maker from enrolling U.S., European patients in trials?

By Adam Feuerstein

Adam's Take

ALS drug maker walks back plan to profit from right-to-try law following heavy criticism

By Adam Feuerstein

Adam's Take

Here come the right-to-try profiteers. The FDA is powerless to stop them

By Adam Feuerstein

Adam's Take

Geron wants J&J to continue a drug development partnership, but new data weaken its case

By Adam Feuerstein

Adam's Take

Questionable data aside, Galmed Pharma soars in a fatty liver stock bubble

By Adam Feuerstein

Adam's Take

Proteostasis cystic fibrosis drug disappoints, easing competitor concerns for Vertex Pharma

By Adam Feuerstein

Adam's Take

Omeros is bullish on its plan for speedy approval of a rare disease drug. Its plan has flaws

By Adam Feuerstein

Adam’s Take

Acadia Pharma conjures black magic to spin a failed depression drug trial

Beyond the headline: Mirati undersells concerning data on its lung cancer immunotherapy

Novartis buys Endocyte for $2.1 billion, causing an outspoken critic to admit he was badly wrong

A biotech company misled investors about its dealings with FDA. It’s time for a reckoning

A tiny fish-oil drug rival trash talks Amarin, but there’s still much to prove

Omeros claims a failed drug study was ‘positive.’ Investors were not fooled

Ahead of Geron blowup, warning signs were visible for those willing to see them

TG Therapeutics’ credibility vanishes with blood cancer drug trial setback

Amarin has investors buzzing about fish oil. Here’s where this biotech feel-good story goes next

Galectin Therapeutics buries bad news in the hype of a combination cancer drug trial

Global Blood’s FDA filing plan for a sickle cell drug is riskier than you think

Amgen emerges as new multiple myeloma drug player, threatening Bluebird, Celgene

Answers to biotech’s burning questions for 2018: winners, floppers, and procrastinators

Can plastic tubes stop livers from failing? Unlikely, but a biotech keeps trying

A gene therapy for overactive bladder? A waste of time and money that trivializes a lifesaving technology

Investors are pouring more money into biotech funds, and stocks are responding

Geron’s prodigious fundraising activity signals low confidence in J&J relationship

Gilead Sciences’ board is looking for a new CEO. Here’s a list of possible contenders

Gilead’s golden era ends with the executive departures of ‘The Johns’

ResTORbio drug study results weaken under scrutiny

Preclinical biotech companies are having an IPO bonanza. What’s the draw for investors?

Celgene is perking up. Here’s what needs to happen for the momentum to continue

Red flags fly over Anavex: What’s stopping the drug maker from enrolling U.S., European patients in trials?

ALS drug maker walks back plan to profit from right-to-try law following heavy criticism

Here come the right-to-try profiteers. The FDA is powerless to stop them

Geron wants J&J to continue a drug development partnership, but new data weaken its case

Questionable data aside, Galmed Pharma soars in a fatty liver stock bubble

Proteostasis cystic fibrosis drug disappoints, easing competitor concerns for Vertex Pharma

Omeros is bullish on its plan for speedy approval of a rare disease drug. Its plan has flaws

Adam’s Take

Sign up for our Daily Recap newsletter